School of Social Work doctoral student, Stephanie Rosado, has been asked to be a panelist for a drug development workshop co-sponsored by the FDA and the Arthritis Foundation. This is a one-day virtual osteoarthritis drug development workshop, set to convene on June 22nd, 2021.
The workshop objectives are to provide forum for open discussion between osteoarthritis experts in academia, industry, non-profit sector, patients, and government with the hope of expediting the development of safe and effective treatments for osteoarthritis. Some key objectives are to identify study designs and clinically meaningful clinical trial endpoints that can be used to demonstrate long-term clinical benefit to patients with osteoarthritis and discuss the role of biomarkers in drug development for the disease. Stephanie will be a panelist for the Q&A session in "Assessment of OA Disease and Progression and Long-term Benefit".